Which tools can I use in daily clinical practice to improve tailoring of treatment for breast cancer? The 2007 St Gallen guidelines and/or Adjuvant! Online

Annals of Oncology

Volumn 19, Issue SUPPL. 7, 2008, Pages

  Cufer T ^a  

^a INSTITUTE OF ONCOLOGY   (Slovenia)

Author keywords

[No Author keywords available]

Indexed keywords

AROMATASE INHIBITOR; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIRUBICIN; ESTROGEN RECEPTOR; FLUOROURACIL; METHOTREXATE; PACLITAXEL; PROGESTERONE RECEPTOR; TAMOXIFEN; TRASTUZUMAB; ANTINEOPLASTIC AGENT;

ADJUVANT THERAPY; BREAST CANCER; BREAST SURGERY; CANCER MORTALITY; CANCER RELAPSE; CANCER SURVIVAL; CLINICAL PRACTICE; COMPUTER PROGRAM; CONFERENCE PAPER; EVIDENCE BASED MEDICINE; HUMAN; INDIVIDUALIZATION; LYMPH NODE METASTASIS; MEDICAL DECISION MAKING; ONLINE SYSTEM; OVERALL SURVIVAL; PATIENT CARE; PRACTICE GUIDELINE; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; RISK ASSESSMENT; TREATMENT OUTCOME; ADJUVANT CHEMOTHERAPY; ALGORITHM; ARTICLE; BREAST TUMOR; DECISION MAKING; FEMALE; METASTASIS; PATHOLOGY;

ALGORITHMS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; DECISION MAKING; FEMALE; HUMANS; NEOPLASM METASTASIS; PHYSICIAN'S PRACTICE PATTERNS; PRACTICE GUIDELINES AS TOPIC;

EID: 53449086917     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdn439     Document Type: Conference Paper

References (25)

1. Levi F, Lucchini F, Negri E, La Vecchia C. Continuing declines in cancer mortality in the European Union. Ann Oncol 2007; 18: 593-595.
2. Berry DA, Cronin KA, Plevritis SK et al. Cancer Intervention and Surveillance Modeling Network (CISNET) Collaborators. Effect of screening and adjuvant therapy on mortality from breast cancer. N Engl J Med 2005; 353: 1784-1792.
3. Ravdin PM, Siminoff LA, Davis GJ et al. Computer program to assist in making decisions about adjuvant therapy for women with early breast cancer. J Clin Oncol 2001; 19: 980-991.
4. http://www.adjuvantonline.com; accessed 12 February 2008.
5. Early Breast Cancer Trialists' Collaborative Group. Polychemotherapy for early breast canceran overview of the randomised trials. Lancet 1998; 352: 930-942.
6. Early Breast Cancer Trialists' Collaborative Group, Tamoxifen for early breast cancer: An overview of the randomised trials. Lancet 1998; 351: 1451-1467.
7. Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: An overview of the randomised trials. Lancet 2005; 356: 1687-1717.
8. Olivotto IO, Bajdik CD, Ravdin PM et al. Population-based validation of the prognostic model ADJUVANT! for early breast cancer. J Clin Oncol 2005; 23: 2716-2725.
9. Palk S, Shak S, Tang G et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med 2004; 351: 2817-2826.
10. Buyse M, Loi S, van't Veer L et al. TRANSBIG Consortium. Validation and clinical utility of a 70-gene prognostic signature for women with node-negative breast cancer. J Natl Cancer Inst 2006; 98: 1183-1192.
11. Foekens JA, Atkins D, Zhang Y et al. Multicenter validation of a gene expression-based prognostic signature in lymph node-negative primary breast cancer. J Clin Oncol 2006; 24: 1665-1671.
12. Mook S, Schmidt MK, Viale G et al. On behalf of the TRANSBIG Consortium. Breast cancer patients with 1-3 positive lymph nodes and a low risk 70-gene profile have an excellent survival. SABCS 2007 abstract 50; http://www.abstracts2view.com/sabcs/sessionindex.php; accessed 12 February 2008.
13. Albain K, Barlow W, Shak S et al. Prognostic and predictive value of the 21 -gene recurrence score assay in postmenopausal, node-positive, ER-positive breast cancer (S8814,INT0100). SABCS 2007 abstract 10, http://www.abstracts2view.com/sabcs/sessionindex.php; accessed 12 February 2008.
14. Paik S, Tang G, Shak S, Kim C et al. Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer. J Clin Oncol 2006; 24: 3726-3734.
15. Colleoni M, Viale G, Zahrieh D et al. Expression of ER, PgR, HER1, HER2, and response: A study of preoperative chemotherapy. Ann Oncol 2007; 18: 1632-1640.
16. Hayes DF, Thor AD, Dressler LG et al. Cancer and Leukemia Group B (CALGB) Investigators. HER2 and response to paclitaxel in node-positive breast cancer. N EngI J Med 2007; 357: 1496-1506.
17. Berry DA, Cirrincione C, Henderson IC et al. Estrogen-receptor status and outcomes of modern chemotherapy for patents with node-positive breast cancer. JAMA 2006; 295: 1658-1567.
18. Colleoni M, Viale G, Zahrieh D et al. Chemotherapy is more effective in patients with breast cancer not expressing steroid hormone receptors: A study of preoperative treatment. Clin Cancer Res 2004; 10: 6622-6628.
19. http://www.nocn.org/professionals/physician-gls/defauft.asp; accessed 12 February 2008.
20. Pestalozzi et al. ESMO Minimal Clinical Recommendations. Ann Oncol 2005; 16 (SuppI 1): I7-i9.
21. Goldhirsch A, Wood WC, Gelber RD et al. Progress and promise: Highlights of the international expert consensus on the primary therapy of early breast cancer 2007. Ann Oncol 2007; 18: 1133-1144.
22. Hébert-Croteau N, Brisson J, Latreille J et al. Compliance with consensus recommendations for systemic therapy is associated with improved survival of women with node-negative breast cancer. J Clin Oncol 2004; 22: 3685-3693.
23. Goldhirsch A, Glick GH, Gelber RD et al. Meeting highlights: international expert consensus on the primary therapy of early breast cancer 2005. Ann Oncol 2005; 16: 1569-1583.
24. Demonty G, Bernard-Marty C, Puglisi F et al. Progress and new standards of care in the management of HER-2 positive breast cancer. Eur J Cancer 2007; 43: 497-509.
25. Albain K, Barlow V, O'Malley F et al. Concurrent (CAFT) versus sequential (CAF-T chemohormonal therapy versus T alone for postmenopausal, node-positive, estrogen and/or progesterone receptor-positive breast cancer: Mature outcomes and new biologic correlates on phase III intergroup trial 0100 (SWOG-8814). Breast Cancer Res Treat 2004; 882: 37 (Abstr).